Generic competition · all medicines · read 12 November 2026

Is there a generic of Fluocinonide, and who makes it?

Fluocinonide appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them. Where both are dated, the first generic approval came between 3 and 4.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Method designed and maintained by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Data compiled automatically from the Orange Book data files, downloaded 12 November 2026. How these pages are made

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Fluocinonide4 dosage-form groups in the Orange Book
16generic makers listed
  1. Fluocinonide appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them.
  2. Where both are dated, the first generic approval came between 3 and 4.7 years after the first brand approval.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Cream, Topical

Four or more generic makers listed

Brand listed as marketed: Vanos. 8 generic makers with 13 generic products listed as marketed; the first generic approval is dated 10 June 1987.

1980198519901995200020052010201520202025203008brand 1984Sun Pharma Canada Inc, first approval 10 June 1987Taro Pharmaceutical Industries Ltd, first approval 19 January 1989Teva Pharmaceuticals Usa Inc, first approval 6 February 1989Cosette Pharmaceuticals Nc Laboratories Llc, first approval 14 February 1992Fougera Pharmaceuticals Inc, first approval 17 October 1994Amneal Pharmaceuticals Llc, first approval 21 August 2018Encube Ethicals Private Ltd, first approval 16 October 2018Zydus Lifesciences Ltd, first approval 10 February 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Sun Pharma Canada Inc10 June 19872
Taro Pharmaceutical Industries Ltd19 January 19891
Teva Pharmaceuticals Usa Inc6 February 19892
Cosette Pharmaceuticals Nc Laboratories Llc14 February 19922
Fougera Pharmaceuticals Inc17 October 19943
Amneal Pharmaceuticals Llc21 August 20181
Encube Ethicals Private Ltd16 October 20181
Zydus Lifesciences Ltd10 February 20201

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Topical

Four or more generic makers listed

Every brand product here is listed as discontinued. 9 generic makers with 9 generic products listed as marketed; the first generic approval is dated 2 December 1988.

1980198519901995200020052010201520202025203009brand 1984Fougera Pharmaceuticals Inc, first approval 27 February 1995Sun Pharma Canada Inc, first approval 31 December 1996Novel Laboratories Inc, first approval 21 July 2017Chartwell Rx Sciences Llc, first approval 23 April 2018Macleods Pharmaceuticals Ltd, first approval 23 April 2018Zydus Pharmaceuticals Usa Inc, first approval 17 July 2018Encube Ethicals Pvt Ltd, first approval 29 November 2018Sciegen Pharmaceuticals Inc, first approval 18 March 2019Quagen Pharmaceuticals Llc, first approval 26 February 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Fougera Pharmaceuticals Inc27 February 19951
Sun Pharma Canada Inc31 December 19961
Novel Laboratories Inc21 July 20171
Chartwell Rx Sciences Llc23 April 20181
Macleods Pharmaceuticals Ltd23 April 20181
Zydus Pharmaceuticals Usa Inc17 July 20181
Encube Ethicals Pvt Ltd29 November 20181
Sciegen Pharmaceuticals Inc18 March 20191
Quagen Pharmaceuticals Llc26 February 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Ointment, Topical

Four or more generic makers listed

Every brand product here is listed as discontinued. 5 generic makers with 5 generic products listed as marketed; the first generic approval is dated 27 December 1991.

19901995200020052010201520202025203005Teva Pharmaceuticals Usa Inc, first approval 27 December 1991Fougera Pharmaceuticals Inc, first approval 26 August 1997Sun Pharma Canada Inc, first approval 30 June 1999Chartwell Rx Sciences Llc, first approval 31 July 2017Xiromed Pharma Espana Sl, first approval 26 November 2019data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Teva Pharmaceuticals Usa Inc27 December 19911
Fougera Pharmaceuticals Inc26 August 19971
Sun Pharma Canada Inc30 June 19991
Chartwell Rx Sciences Llc31 July 20171
Xiromed Pharma Espana Sl26 November 20191

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Gel, Topical

One to three generic makers listed

Every brand product here is listed as discontinued. 3 generic makers with 3 generic products listed as marketed; the first generic approval is dated 7 February 1989.

19901995200020052010201520202025203003Fougera Pharmaceuticals Inc, first approval 30 December 1994Sun Pharma Canada Inc, first approval 29 July 1997Padagis Us Llc, first approval 19 June 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Fougera Pharmaceuticals Inc30 December 19941
Sun Pharma Canada Inc29 July 19971
Padagis Us Llc19 June 20181

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

What do pharmacies pay for Fluocinonide?

The CMS NADAC survey tracks what pharmacies pay to acquire Fluocinonide: 5 products with year-end prices from 2013 to 2026. See the acquisition cost history on RxGrab. It is a pharmacy cost, not a retail price, and this page does not say how it relates to the number of makers listed above.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.